CepTor Corporation

New compound patents pending for Myodur in muscular dystrophy

Published in Pharma Law Weekly, May 24th, 2005

CepTor Corporation (CEPO) announced that intellectual property filings have been made to further strengthen its patent position for the company's muscle cell targeted protease inhibitor platform technology.

More specifically, CepTor has filed to receive an additional 20 years of compound protection for oral delivery of Myodur with accompanied use protection in Duchenne muscular dystrophy (DMD) and other neuromuscular diseases.

William Pursley, CepTor's chairman and CEO stated, "Protecting our property remains a never-ending priority. We are unaware of any other specific muscle cell targeted, protease inhibiting compounds being used or developed to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2005-05-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry